Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342340 | 0.90 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL8662011 | 0.84 | HTR1D (0.82) | HTR1DHTR1B | |
| SCHEMBL7475794 | 0.84 | HTR1D (0.76) | HTR1DHTR1B | |
| SCHEMBL7480186 | 0.81 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL7479931 | 0.81 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL7476512 | 0.81 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL4342313 | 0.81 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL8177129 | 0.80 | HTR1D (0.78) | HTR1DHTR1B | |
| SCHEMBL8657524 | 0.80 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL8659040 | 0.79 | HTR1D (0.76) | HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | claimed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | HTR1D 3404/4885HTR1B 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.